Recent Updates
Recently added Catalysts
RARE Negative Sentiment Score: 25/100

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

Key Takeaway: Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for allegedly failing to disclose material information during a defined class period. This follows the recent failure of their Phase 3 studies for setrusumab, which did not demonstrate a significant reduction in fracture rates for osteogenesis imperfecta patients. As a result, the company has begun evaluating operations for potential expense reductions. Significant stock price decline of around 42% occurred after the announcement of study results.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ultragenyx faces a class action lawsuit due to failure to disclose material information.
  • The company's Phase 3 studies for setrusumab did not show significant efficacy, leading to concerns about its product pipeline.
  • Stock prices fell by approximately 42%, reflecting investor loss and confidence issues.

Full Press Release Details

NEW ORLEANS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Ultragenyx investors should visit us at https://claimsfiler.com/cases/nasdaq-rare/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Ultragenyx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.” On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file claims against Ultragenyx?

Investors must file claims by April 6, 2026.

What triggered the securities class action against Ultragenyx?

Ultragenyx failed to disclose key information, violating federal laws.

How much did Ultragenyx's shares drop following the study results?

Shares fell approximately 42% after the Phase III study announcement.

Who can investors contact for more information?

Investors can visit ClaimsFiler or call toll-free at 844-367-9658.

Where is the class action lawsuit filed?

It's pending in the United States District Court for the Southern District of New York.

Last updated: Feb 12, 2026